Incyte Corporation - Product Pipeline Review - 2016

  • ID: 3766803
  • Company Profile
  • 84 pages
  • Global Markets Direct
  • Incyte Corporation
1 of 4
Incyte Corporation - Product Pipeline Review - 2016

Summary

The report ‘Incyte Corporation - Product Pipeline Review - 2016’, provides an overview of the Incyte Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Incyte Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Incyte Corporation
- The report provides overview of Incyte Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Incyte Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Incyte Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Incyte Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Incyte Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Incyte Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Incyte Corporation Snapshot

Incyte Corporation Overview

Key Information

Key Facts

Incyte Corporation - Research and Development Overview

Key Therapeutic Areas

Incyte Corporation - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Incyte Corporation - Pipeline Products Glance

Incyte Corporation - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Incyte Corporation - Early Stage Pipeline Products

IND/CTA Filed Products/Combination Treatment Modalities

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Incyte Corporation - Drug Profiles

(INCB-039110 + INCB-040093)

Product Description

Mechanism of Action

R&D Progress

epacadostat

Product Description

Mechanism of Action

R&D Progress

INCB-40093

Product Description

Mechanism of Action

R&D Progress

itacitinib adipate

Product Description

Mechanism of Action

R&D Progress

ruxolitinib phosphate

Product Description

Mechanism of Action

R&D Progress

INCB-50465

Product Description

Mechanism of Action

R&D Progress

INCB-52793

Product Description

Mechanism of Action

R&D Progress

INCB-53914

Product Description

Mechanism of Action

R&D Progress

INCB-54329

Product Description

Mechanism of Action

R&D Progress

INCB-54828

Product Description

Mechanism of Action

R&D Progress

INCB-59872

Product Description

Mechanism of Action

R&D Progress

SHR-1210

Product Description

Mechanism of Action

R&D Progress

INCAGN-1876

Product Description

Mechanism of Action

R&D Progress

INCAGN-1949

Product Description

Mechanism of Action

R&D Progress

INCB-57643

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit LAG3 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit TIM3 for Oncology

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Oncology

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Chronic Inflammation

Product Description

Mechanism of Action

R&D Progress

Incyte Corporation - Pipeline Analysis

Incyte Corporation - Pipeline Products by Target

Incyte Corporation - Pipeline Products by Route of Administration

Incyte Corporation - Pipeline Products by Molecule Type

Incyte Corporation - Pipeline Products by Mechanism of Action

Incyte Corporation - Recent Pipeline Updates

Incyte Corporation - Dormant Projects

Incyte Corporation - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

aderbasib

INCB-047986

itacitinib adipate

ruxolitinib phosphate

Incyte Corporation - Company Statement

Incyte Corporation - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Incyte Corporation, Key Information

Incyte Corporation, Key Facts

Incyte Corporation - Pipeline by Indication, 2016

Incyte Corporation - Pipeline by Stage of Development, 2016

Incyte Corporation - Monotherapy Products in Pipeline, 2016

Incyte Corporation - Combination Treatment Modalities in Pipeline, 2016

Incyte Corporation - Partnered Products in Pipeline, 2016

Incyte Corporation - Partnered Products/ Combination Treatment Modalities, 2016

Incyte Corporation - Out-Licensed Products in Pipeline, 2016

Incyte Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016

Incyte Corporation - Phase II, 2016

Incyte Corporation - Phase I, 2016

Incyte Corporation - IND/CTA Filed, 2016

Incyte Corporation - Preclinical, 2016

Incyte Corporation - Discovery, 2016

Incyte Corporation - Pipeline by Target, 2016

Incyte Corporation - Pipeline by Route of Administration, 2016

Incyte Corporation - Pipeline by Molecule Type, 2016

Incyte Corporation - Pipeline Products by Mechanism of Action, 2016

Incyte Corporation - Recent Pipeline Updates, 2016

Incyte Corporation - Dormant Developmental Projects,2016

Incyte Corporation - Discontinued Pipeline Products, 2016

Incyte Corporation, Subsidiaries

List of Figures

Incyte Corporation - Pipeline by Top 10 Indication, 2016

Incyte Corporation - Pipeline by Stage of Development, 2016

Incyte Corporation - Monotherapy Products in Pipeline, 2016

Incyte Corporation - Combination Treatment Modalities in Pipeline, 2016

Incyte Corporation - Partnered Products in Pipeline, 2016

Incyte Corporation - Out-Licensed Products in Pipeline, 2016

Incyte Corporation - Pipeline by Top 10 Target, 2016

Incyte Corporation - Pipeline by Route of Administration, 2016

Incyte Corporation - Pipeline by Molecule Type, 2016

Incyte Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll